Boehringer Ingelheim’s Formula For Scaling Transformation, Digitization
Executive Summary
Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.
You may also be interested in...
GSK CTO, Boehringer Exec On The Metaverse And Pharma’s Foot In The Door
Big pharma executives discuss the transformative potential of the metaverse in the life sciences segment and how things are shaping in the virtual world amid the hype. GSK’s senior VP and chief technology officer outlines to Scrip gains made deploying digital twins and bots.
Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
How Boehringer Ingelheim Deepened Its Digital Transformation
While many pharma companies have integrated digital tools like cloud services into their operations, some are later adopters. Boehringer Ingelheim is one of the most recent companies to announce a move to a cloud-based R&D platform as part of the company’s commitment to digital transformation. For those still considering how to go about the shift to digital, rolling things out in the right order is one important factor, an EY expert tells In Vivo.